The role of veto cells in bone marrow transplantation

Current Opinion in Organ Transplantation

Volumn 11, Issue 4, 2006, Pages 366-372

  Reisner, Yair ^a   Shlomit, Reich Zeliger ^a   Bachar Lustig, Esther ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

CD8; FasL; Nonmyeloablative; Tolerance; Transforming growth factor ; Veto

Indexed keywords

CD34 ANTIGEN; FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 7; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; RAPAMYCIN; TRANSFORMING GROWTH FACTOR BETA; VIRUS ANTIGEN;

BONE MARROW TRANSPLANTATION; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL POPULATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOSE RESPONSE; GENE TRANSFER; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; HLA SYSTEM; HUMAN; LETHALITY; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; TRANSGENIC MOUSE; VETO CELL; WHOLE BODY RADIATION;

EID: 33746352041     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/01.mot.0000236698.45210.3e     Document Type: Review

References (49)

1. Mielcarek M, Storb R. Graft-vs-host disease after nonmyeloablative hematopoietic cell transplantation. Leuk Lymphoma 2005; 46:1251-1260. An update of clinical outcome in nonmyeloablative transplants.
2. Lapidot T, Terenzi A, Singer TS, et al. Enhancement by dimethyl myleran of donor type chimerism in murine recipients of bone marrow allografts. Blood 1989; 73:2025-2032.
3. Uharek L, Gassmann W, Glass B, et al. Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation. Blood 1992; 79:1612-1621.
4. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339:1186-1193.
5. Reisner Y, Martelli MF. Stem cell escalation enables HLA-disparate haematopoietic transplants in leukaemia patients. Immunol Today 1999; 20:343-347.
6. + progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 2001; 27:777-783.
7. Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23:3447-3454.
8. Rachamim N, Gan J, Segall H, et al. Tolerance induction by 'megadose' hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host antidonor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation 1998; 65:1386-1393.
9. + cells. Blood 2002; 99:4174-4181.
10. Gur H, Krauthgamer R, Bachar-Lustig E, et al. Immune regulatory activity of CD34+ progenitor cells: evidence for a deletion-based mechanism mediated by TNF-α. Blood 2005; 105:2585-2593. Demonstration of the role of death molecules other than FasL in the veto activity of CD34 stem cells.
11. Miller RG. An immunological suppressor cell inactivating cytotoxic T-lymphocyte precursor cells recognizing it. Nature 1980; 287:544-546.
12. Muraoka S, Miller RG. Cells in murine fetal liver and in lymphoid colonies grown from fetal liver can suppress generation of cytotoxic T lymphocytes directed against their self antigens. J Immunol 1983; 131:45-49.
13. Claesson MH, Miller RG. Functional heterogeneity in allospecific cytotoxic T lymphocyte clones. I. CTL clones express strong antiself suppressive activity. J Exp Med 1984; 160:1702-1716.
14. Fink PJ, Rammensee HG, Benedetto JD, et al. Studies on the mechanism of suppression of primary cytotoxic responses by cloned cytotoxic T lymphocytes. J Immunol 1984; 133:1769-1774.
15. Fink PJ, Rammensee HG, Bevan MJ. Cloned cytolytic T cells can suppress primary cytotoxic responses directed against them. J Immunol 1984; 133:1775-1781.
16. Zhang LI, Martin DR, Fung-Leung WP, et al. Peripheral deletion of mature CD8+ antigen-specific T cells after in vivo exposure to male antigen. J Immunol 1992; 148:3740-3745.
17. Thomas JM, Carver FM, Kasten-Jolly J, et al. Further studies of veto activity in rhesus monkey bone marrow in relation to allograft tolerance and chimerism. Transplantation 1994; 57:101-115.
18. Verbanac KM, Carver FM, Haisch CE, Thomas JM. A role for transforming growth factor-beta in the veto mechanism in transplant tolerance. Transplantation 1994; 57:893-900.
19. George JF, Goldstein DR, Thomas JM. Donor bone marrow and transplantation tolerance: historical perspectives, molecular mechanisms and future directions [review]. Int J Mol Med 1999; 4:475-482.
20. Reich-Zeliger S, Zhao Y, Krauthgamer R, et al. Antithird party CD8+ CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite. Immunity 2000; 13:507-515.
21. + antiviral T cells by viral antigen-positive veto cells. J Virol 1999; 73:3826-3834.
22. Sambhara SR, Miller RG. Programmed cell death of T cells signaled by the T cell receptor and the alpha 3 domain of class I MHC. Science 1991; 252:1424-1427.
23. Asiedu C, Meng Y, Wang W, et al. Immunoregulatory role of CD8a in the veto effect: transforming growth factor-β1 activation. Transplantation 1999; 67:372-380.
24. Qi Y, Berg R, Singleton MA, et al. Hybrid antibody mediated veto of cytotoxic T lymphocyte responses. J Exp Med 1996; 183:1973-1980.
25. George J, Thomas J. The molecular mechanisms of veto mediated regulation of alloresponsiveness. J Mol Med 1999; 77:519-526.
26. Cheruku R, Uberti J, Martilotti F, Kaplan J. Generation of lymphokine-activated killer cells with veto and natural suppressor activity from patients with leukemias and lymphomas. Transplantation 1993; 56:1037-1040.
27. Uberti J, Martilotti F, Chou TH, Kaplan J. Human lymphokine activated killer (LAK) cells suppress generation of allospecific cytotoxic T cells: implications for use of LAK cells to prevent graft-versus-host disease in allogeneic bone marrow transplantation. Blood 1992; 79:261-268.
28. Reich-Zeliger S, Bachar-Lustig E, Gan J, Reisner Y. Tolerance induction by veto CTLs in the TCR transgenic 2C mouse model. I. Relative reactivity of different veto cells. J Immunol 2004; 173:6654-6659.
29. George JF, Sweeney SD, Kirklin JK, et al. An essential role for Fas ligand in transplantation tolerance induced by donor bone marrow. Nat Med 1998; 4:333-335.
30. Reich-Zeliger S, Gan J, Bachar-Lustig E, Reisner Y. Tolerance induction by veto CTLs in the TCR transgenic 2C mouse model. II. Deletion of effector cells by Fas-Fas ligand apoptosis. J Immunol 2004; 173:6660-6666.
31. Rich RF, Cook WJ, Green WR. Spontaneous in vivo retrovirus-infected T and B cells, but not dendritic cells, mediate antigen-specific Fas ligand/Fas-dependent apoptosis of antiretroviral CTL. Virology 2006; 346:287-300. An interesting demonstration of the role of Fas/FasL in veto CTLs presenting viral antigen and thereby deleting antiviral effector cells.
32. Green WR. T cytotoxic lymphocytes to endogenous mouse retroviruses and mechanisms of retroviral escape. Immunol Rev 1999; 168:271-286.
33. Hiruma K, Gress RE. Cyclosporine A and peripheral tolerance: inhibition of veto cell-mediated clonal deletion of postthymic precursor cytotoxic T lymphocytes. J Immunol 1992; 149:1539-1547.
34. Reich-Zeliger S, Hanoch T, Seger R, Reisner Y. The role of ERK5 signaling in tolerance induction by veto CTLs [abstract]. Blood 2005; 106:3302.
35. Chrobak P, Gress RE. Veto activity of activated bone marrow does not require perforin and Fas ligand. Cell Immunol 2001; 208:80-87.
36. Bachar-Lustig E, Reich-Zeliger S, Reisner Y. Antithird-party veto CTLs overcome rejection of hematopoietic allografts: synergism with rapamycin and BM cell dose. Blood 2003; 102:1943-1950.
37. Taylor RM, Cheeseman P, Rela M, et al. Use of calcineurin inhibitors in pediatric liver transplantation: a single-center experience. Transplant Proc 2002; 34:1974-1975.
38. Steiner D, Brunicki N, Bachar-Lustig E. Overcoming T cell mediated rejection of bone marrow allografts by Treg cells: synergism with veto cells and Rapamycin. Exp Hematol 2006; In press.
39. Steiner D, Brunicki N, Blazar BR, et al. Tolerance induction by third-party 'off-the-shelf' CD4+CD25+ Treg cells. Exp Hematol 2006; 34:66-71.
40. Anderson KM, Zimring JC. Rapamycin prolongs susceptibility of responding T cells to tolerance induction by CD8+ veto cells. Transplantation 2006; 81:88-94. Interesting proposal that rapamycin enhances veto activity by increasing the susceptibility of the effector cells after activation by the relevant stimulator cells.
41. Reich-Zeliger S, Bachar-Lustig E, Reisner Y. Effective deletion of anti-donor host memory effector cells by anti3rd party veto CTLs: implications to tolerance induction in presensitized bone marrow recipients [abstract]. Blood 2004; 104:44.
42. Aviner S, Yao X, Krauthgamer R, et al. Large-scale preparation of human antithird-party veto cytotoxic T lymphocytes depleted of graft-versus-host reactivity: a new source for graft facilitating cells in bone marrow transplantation. Hum Immunol 2005; 66:644-652. Description of the methodology for generation of human veto CTLs depleted of GVH reactivity.
43. Fowler DH, Gress RE. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymphoma 2000; 38:221-234.
44. Jung U, Foley JE, Erdmann AA, et al. CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects. Blood 2004; 102:3439-3446.
45. Erdmann AA, Jung U, Foley JE, et al. Co-stimulated/Tc2 cells abrogate murine marrow graft rejection. Biol Blood Marrow Transplant 2004; 10:604-613.
46. Fowler D, Hou J, Foley J, et al. Phase I clinical trial of donor T-helper type-2 cells after immunoablative, reduced intensity allogeneic PBSC transplant. Cytotherapy 2002; 4:429-430.
47. Fowler DH, Bishop MR, Gress RE. Immunoablative reduced-intensity stem cell transplantation: potential role of donor Th2 and Tc2 cells. Semin Oncol 2004; 31:56-67.
48. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukaemia. Proc Natl Acad Sci U S A 2003; 100:2742-2747.
49. Nair SK, Heiser A, Boczkowski D, et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000; 6:1011-1017.